Published: 2021-01-27 14:27 | Updated: 2021-01-27 14:39

Current calls, week 4, 2021

Tips from KI Grants Office about current calls.

Swedish and Nordic calls

Call for Scientific eMeeting Grants 2021 (Round 1)

Karolinska Institutet KIRCNET Scientific Online Meeting Grants 2021 (Round 1)

KIRCNET hereby invites applications from PhD students and post-doc researchers for reimbursement of registration cost to attend virtual scientific meeting in Cardiovascular and Respiratory fields.

Eligibility: Applications are invited from registered doctoral students admitted at Karolinska Institutet and Postdoc researchers working at KI. Priority is given to those whose abstracts have been accepted for oral presentation or ePoster.

Other conditions apply: The virtual meeting the applicant is attending must be related to Cardiovascular and Respiratory research fields.

Closing date: March 12, 2021

Further information

Forskningsanslag för HIV/AIDS-forskning

Stiftelsen Läkare Mot AIDS Forskningsfond ledigförklarar härmed forskningsanslag för studier som syftar till behandling av HIV-infektion eller dess följdtillstånd och till förebyggande åtgärder.

Closing date: 1 March 2021

Further information

Inga Sandeborgs pris – Swedish Society of Medicine

Detta belönar vetenskapliga arbeten rörande Alzheimers sjukdom eller andra degenerativa sjukdomar i centrala nervsystemet. Priset är värt SEK 125,000.

Closing date: 1 March 2021 

Further information

Bengt Winblads pris – Swedish Society of Medicine

Detta belönar insatser inom neurovetenskaplig forskning inom geriatrik med huvudsaklig inriktning mot demenssjukdomar och Alzheimderforskningen. Priset är värt SEK 150,000.

Closing date: 1 March 2021 

Further information

Research call: One Health interventions to prevent or reduce the development and transmission of Antimicrobial Resistance – Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)

This aims to understand the impact of interventions on the development and transmission of antibiotic resistance and to design, implement, evaluate and compare interventions that will have an impact on preventing or reducing the development and transmissions of antibiotic resistance in and between the one health settings.

Closing date: 16 March 2021

Further information

Project support: Saving Lives at Birth in Low-Resource Settings – Laerdal Foundation

Saving lives at birth in low-resource settings grants Laerdal Foundation These support practically oriented projects aimed at achieving the UN millennium development goal three, which is to reduce infant and child mortality rates and maternal deaths by two-thirds from 2010 to 2030. Up to 20 projects are available per year, worth up to USD 50,000 each but higher amounts may be awarded to regional initiatives, or particular educational or collaborative initiatives.

Closing date: 1 April 2021

Further information

European calls

EFSD/Novo Nordisk Foundation future leaders award programme - European Foundation for the Study of Diabetes and the Novo Nordisk Foundation

The European Foundation for the Study of Diabetes and the Novo Nordisk Foundation invite applications for their future leaders award programme. This supports clinical and basic scientists in transitioning from postdoctoral clinical fellow to a tenured faculty position in European diabetes research.

Applicants must have received their PhD or MD not more than 10 years before the start of the award and not yet holding a tenured academic faculty appointment. For clinicians holding more than one qualifying degree or with a clinical specialist degree or board certification, the time since the first degree may not exceed 12 years before the start of the award. Applicants must be paid-up members of the association.

Grants are worth DKK 5 million each over five years.

Closing date: 1 March 2021

Further information

Call for proposals for transnational access projects - EASI-Genomics 

EASI-Genomics invites proposals for its transnational access projects. This supports researchers in next-generation sequencing, high-end genomic applications and genomic data analysis. EASI-Genomics will support integrative projects covering expertise that is not available at the applicants’ home institution sites including high-throughput and cutting-edge sequencing, complex bioinformatic analysis, DNA extraction and data analysis of existing data sets. Proposals are accepted for the following topics:

  • sequencing of ancient DNA;
  • single-cell genomics;
  • spatial transcriptomics and in situ sequencing;
  • identification of epigenetic signatures;
  • long-read sequencing with Oxford nanopore technology;
  • formalin-fixed paraffin embedded RNA and exome sequencing.

Applicants may be academic researchers, research groups, scientific institutions or companies based world wide. Applicants cannot request access to facilities in their home country. External users may also apply.

Funding covers consumables, computation and personnel.

Closing date: 1 March 2021

Further information

EFSD/Boehringer Ingelheim European research programme on multi-system challenges in diabetes - European Foundation for the Study of Diabetes and Boehringer Ingelheim

The European Foundation for the Study of Diabetes and Boehringer Ingelheim invite applications for their European research programme on multi-system challenges in diabetes. This supports projects that advance current knowledge in the inter-organ crosstalk and related pathophysiology in diabetes and its complications through innovative basic or clinical research.

Applications are invited from single or groups of non-profit institutions in Europe and associated countries. The PI and any co-investigators must be employed full-time at a non-profit institution, and the study must be conducted at their place of work.

Funding is worth up to €100,000 for basic or clinical research projects with the exclusion of clinical trials. Projects may last for one year or longer. In exceptional cases, up to €300,000 may be considered.

Closing date: 6 April 2021

Further information

Young investigator programme - European Molecular Biology Organisation (FORECAST)

The European Molecular Biology Organisation invites applications for its young investigator programme. This supports junior group leaders in the field of life sciences to set up their first independent laboratories. Applications are accepted from candidates who:

  • have been an independent group leader for at least one year at the pre-application deadline and less than four years on 1 January in the year of application;
  • work in the life sciences in a European Molecular Biology Conference member state, associate member state or co-operating partner country;
  • have obtained sufficient funding to run their laboratory;
  • have published at least one last author research paper in an international peer reviewed journal;
  • are 40 years old or younger on 1 January in the year of application, unless exceptional circumstances have significantly delayed career progression.

Awards are worth €15,000 each paid to investigators in their second year. Investigators may also apply for small grants of up to €10,000 per year.

Closing date: 1 April 2021 (Forecast). We have no information from the funder yet about the next call. Based on past experience, we forecast the deadline to be around April 2021. This call is repeated once a year.

Further information

US calls

Federal Funding agencies

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed), NIH

This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.

Closing date: May 6, 2021, November 4, 2021, May 5, 2021, November 3, 3022, May 4, 2023. All applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-20-284

Further information   

Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional), NIH

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative on-demand, event -driven and long-acting systemic and non-systemic multipurpose prevention technologies (MPT).  It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy, and (HIV/STI) and non-HIV STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.   

Closing date: May 6, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-19-209

Further information 

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional), NIH

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed in the FOA.

Closing date: Standard dates / Standard AIDS dates apply, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): PAR-19-275

Further information 

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional), NIH

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Closing date: Standard dates, by 5:00 PM local time of applicant organization. 

Funding Opportunity Announcement (FOA): PAR-18-206

Further information  



Angelman syndrome grants, Angelman Syndrome Foundation, US

The Angelman Syndrome Foundation invites proposals for the Angelman syndrome grants. These support research on Angelman syndrome. Studies related to communication, behavioural issues and identification of issues and treatments that impact the daily life of people with Angelman syndrome and their families are of particular interest. The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:

  • Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion. 
  • Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
  • Projects studying delivery of therapies and potential for improvement.
  • Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.

Proposals that do not address these topics are still welcome and will be given full consideration.

Budget: One- or two-year grants are awarded for various amounts of up to $100,000 per year. Indirect costs of up to 10% will be allowed (to be included in the total budget amount not to exceed $100,000 per year)

Closing date: April 15, 2021, 11:59 p.m. CT

Further information